Insider Purchase: President & Head of R & D of $RGLS Buys 12,000 Shares

Preston Klassen, President & Head of R&D of $RGLS, purchased 12,000 shares for approximately $95,852, increasing his holdings by 33.3% to 48,055 shares. Over the past six months, $RGLS insiders have executed more sales (7) than purchases (3), while institutional investors showed mixed sentiment in Q1 2025, with some firms significantly increasing their positions (Federated Hermes, Baker Bros.) and others reducing or liquidating their stakes (Octagon Capital, Millennium Management). Wells Fargo issued an "Overweight" rating on $RGLS on March 27, 2025.

Analysis

Regulus Therapeutics ($RGLS) has experienced notable insider and institutional trading activity. Preston Klassen, President & Head of R&D, significantly increased his stake with a 12,000 share purchase valued at approximately $95,852, boosting his holdings by 33.3% to 48,055 shares. This individual show of confidence contrasts with the broader insider trend over the past six months, which saw 7 sales versus 3 purchases. Specifically, CEO Joseph P. Hagan engaged in both buying (50,000 shares for $54,260) and selling (127,054 shares for $160,494), while the CFO and General Counsel exclusively sold shares. Institutional sentiment in Q1 2025 was also divided: 30 institutions added $RGLS shares while 46 reduced positions. Notably, Federated Hermes Inc. added 2.97 million shares (+$5.19M) and Baker Bros. Advisors LP initiated a significant position with 2.69 million shares (+$4.71M). Conversely, Octagon Capital Advisors LP reduced its holding by 93.8% (-4.55M shares, -$7.96M), and Millennium Management LLC and Adage Capital Partners GP, L.L.C. fully liquidated their positions, shedding 2.19M shares (-$3.84M) and 2.00M shares (-$3.50M) respectively. Vivo Capital also substantially decreased its stake by 46.1% (-2.30M shares, -$4.03M). On the analyst front, Wells Fargo issued an "Overweight" rating on March 27, 2025, representing the sole buy rating reported among recent analyst actions.

Key Decisions for Investors

• Investors should note the recent significant insider purchase by the Head of R&D as a potentially positive signal, but weigh it against the net selling activity by other insiders over the past six months.
• The divergent institutional flows, with some large funds establishing or increasing positions while others significantly reduce or exit, warrant careful scrutiny of the underlying reasons for these moves and may indicate a stock undergoing a shift in its investor base.
• Given the mixed signals from insider and institutional activity, alongside a positive analyst rating, investors should conduct thorough due diligence, monitoring future filings for continued insider conviction and shifts in institutional sentiment before making significant allocation decisions.